Key facts
- It has raised $41.5M; the latest was Early Stage VC in Oct 2024.
- Notable investors include Alumni Ventures, FJ Labs, Global Founders Capital, AlleyCorp, Kinled Holding — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Transcend Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Transcend Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Transcend Therapeutics
Operator of a neuroscience-focused clinical-stage company intended to develop psychoactive medicines for neuropsychiatric disease. The company's compound targets specific brain areas implicated in the pathophysiology of neuropsychiatric disorders, enabling doctors to help patients promote positive changes in brain function and behavior.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 14
- Website
- transcendtherapeutics.com/
- Ownership
- Privately Held (backing)
Transcend Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Transcend Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Transcend Therapeutics in its N-PORT filings yet. We sweep new filings monthly.